Report Content
Chapter 1 Methodology & Scope
1.1 Market definitions
1.2 Base estimates and working
1.3 Forecast parameters
1.4 Data validation
1.5 Data sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Unpaid sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 Fabry disease treatment industry 3600 synopsis, 2017 - 2030 (USD Million)
2.1.1 Business trends
2.1.2 Treatment type trends
2.1.3 Regional trends
Chapter 3 Fabry Disease Treatment Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2030 (USD Million)
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Rising cases of Fabry disease across the globe
3.3.1.2 Growing awareness among specialist and physicians
3.3.1.3 Advancements in Fabry disease treatment therapies
3.3.1.4 Rising health awareness and demand for early-stage diagnosis
3.3.2 Industry pitfalls & challenges
3.3.2.1 High treatment cost
3.4 Growth potential analysis
3.4.1 By treatment
3.5 COVID- 19 impact analysis
3.6 Future market trends
3.7 Pricing analysis
3.8 Brand analysis
3.9 Gap analysis
3.10 Product pipeline analysis
3.11 Current therapies
3.12 Epidemology Scenario
3.13 Reimbursement scenario
3.14 Regulatory landscape
3.14.1 U.S.
3.14.2 Europe
3.15 Porter's Analysis
3.16 Competitive landscape, 2021
3.16.1 Company matrix analysis, 2021
3.16.2 Company market share analysis, 2021
3.16.2.1 Global
3.17 PESTLE Analysis
Chapter 4 Fabry Disease Treatment Market, By Treatment Type
4.1 Key segment trends
4.2 Enzyme Replacement Therapy (ERT)
4.2.1 Market size, by region, 2017 - 2030 (USD Million)
4.2.2 By Drug Type
4.2.2.1 Agalsidase Alpa
4.2.2.1.1 Market size, by region, 2017 - 2030 (USD Million)
4.2.2.2 Agalsidase Beta
4.2.2.2.1 Market size, by region, 2017 - 2030 (USD Million)
4.2.3 By End-use
4.2.3.1 Physician office
4.2.3.1.1 Market size, by region, 2017 - 2030 (USD Million)
4.2.3.2 Home settings
4.2.3.2.1 Market size, by region, 2017 - 2030 (USD Million)
4.3 Chaperone Therapy
4.3.1 Market size, by region, 2017 - 2030 (USD Million)
Chapter 5 Fabry Disease Treatment Market, By Region
5.1 Key regional trends
5.2 North America
5.2.1 Market size, by country, 2017 - 2030 (USD Million)
5.2.2 Market size, by treatment type, 2017 - 2030 (USD Million)
5.2.2.1 Market size, by drug type, 2017 – 2030 (USD Million)
5.2.2.2 Market size, by end-use, 2017 -2030 (USD Million)
5.2.3 U.S.
5.2.3.1 Market size, by treatment type, 2017-2030 (USD Million)
5.2.3.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.2.3.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.2.4 Canada
5.2.4.1 Market size, by treatment type, 2017-2030 (USD Million)
5.2.4.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.2.4.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.3 Europe
5.3.1 Market size, by country, 2017 - 2030 (USD Million)
5.3.2 Market size, by treatment type, 2017 - 2030 (USD Million)
5.3.2.1 Market size, by drug type, 2017 – 2030 (USD Million)
5.3.2.2 Market size, by end-use, 2017 -2030 (USD Million)
5.3.3 Germany
5.3.3.1 Market size, by treatment type, 2017-2030 (USD Million)
5.3.3.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.3.3.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.3.4 UK
5.3.4.1 Market size, by treatment type, 2017-2030 (USD Million)
5.3.4.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.3.4.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.3.5 France
5.3.5.1 Market size, by treatment type, 2017-2030 (USD Million)
5.3.5.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.3.5.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.3.6 Spain
5.3.6.1 Market size, by treatment type, 2017-2030 (USD Million)
5.3.6.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.3.6.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.3.7 Italy
5.3.7.1 Market size, by treatment type, 2017-2030 (USD Million)
5.3.7.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.3.7.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.4 Asia Pacific
5.4.1 Market size, by country, 2017 - 2030 (USD Million)
5.4.2 Market size, by treatment type, 2017 - 2030 (USD Million)
5.4.2.1 Market size, by drug type, 2017 – 2030 (USD Million)
5.4.2.2 Market size, by end-use, 2017 -2030 (USD Million)
5.4.3 Japan
5.4.3.1 Market size, by treatment type, 2017-2030 (USD Million)
5.4.3.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.4.3.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.4.4 China
5.4.4.1 Market size, by treatment type, 2017-2030 (USD Million)
5.4.4.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.4.4.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.4.5 Australia
5.4.5.1 Market size, by treatment type, 2017-2030 (USD Million)
5.4.5.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.4.5.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.4.6 India
5.4.6.1 Market size, by treatment type, 2017-2030 (USD Million)
5.4.6.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.4.6.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.4.7 South Korea
5.4.7.1 Market size, by treatment type, 2017-2030 (USD Million)
5.4.7.1.1 Market size, by drug type, 2017 - 2030 (USD Million)
5.4.7.1.2 Market size, by end-use, 2017 -2030 (USD Million)
5.5 ROW
5.5.1 Market size, by treatment type, 2017 - 2030 (USD Million)
5.5.1.1 Market size, by drug type, 2017 – 2030 (USD Million)
5.5.1.2 Market size, by end-use, 2017 -2030 (USD Million)
Chapter 6 Company Profiles
6.1 Competitive dashboard, 2021
6.2 Sanofi SA
6.2.1 Business Overview
6.2.2 Financial Data
6.2.3 Product Landscape
6.2.4 Strategic Outlook
6.2.5 SWOT Analysis
6.3 Takeda Pharmaceuticals Co.
6.3.1 Business Overview
6.3.2 Financial Data
6.3.3 Product Landscape
6.3.4 Strategic Outlook
6.3.5 SWOT Analysis
6.4 Amicus Therapeutics, Inc.
6.4.1 Business Overview
6.4.2 Financial Data
6.4.3 Product Landscape
6.4.4 Strategic Outlook
6.4.5 SWOT Analysis
6.5 JCR Pharmaceuticals Co Ltd.
6.5.1 Business Overview
6.5.2 Financial Data
6.5.3 Product Landscape
6.5.4 Strategic Outlook
6.5.5 SWOT Analysis
6.6 ISU Abxis Co. Ltd
6.6.1 Business Overview
6.6.2 Financial Data
6.6.3 Product Landscape
6.6.4 Strategic Outlook
6.6.5 SWOT Analysis
